1 unchanged sentence
During the three months ended
−Removed: September 30, 2024, no director or officer of the Company adopted or terminated a Rule 10b5-1 trading arrangement
−Removed: or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.
+Added: March 31, 2025, no director or officer of the Company adopted or terminated a Rule 10b5-1 trading arrangement or non-Rule
+Added: 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.
EXHIBIT INDEX
11 unchanged sentences
Current Report on Form 8-K (File No.
+Added: Certificate of Designation of Series D Preferred Stock, dated November 16, 2022.
+Added: Current Report on Form 8-K (File No.
+Added: November 16, 2022
Amended and Restated Bylaws of Phio Pharmaceuticals Corp.
Current Report on Form 8-K (File No.
−Removed: Form of Series C/D Warrant, dated July 12, 2024.
+Added: Form of Warrant.
+Added: Amendment No.
+Added: 1 to the Registration Statement on Form S-1 (File No.
+Added: September 28, 2018
+Added: Form of Placement Agent Warrant.
Current Report on Form 8-K (File No.
−Removed: July 12, 2024
−Removed: Form of Placement Agent Warrant, dated July 12, 2024.
+Added: November 19, 2019
+Added: Form of Warrant.
Current Report on Form 8-K (File No.
+Added: February 6, 2020
+Added: Form of Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: February 13, 2020
+Added: Form of Underwriter Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: February 13, 2020
+Added: Form of Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: April 2, 2020
+Added: Form of Common Stock Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: January 25, 2021
+Added: Form of Placement Agent Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: February 17, 2021
+Added: Form of Series A Common Stock Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: April 20, 2023
+Added: Form of Series B Common Stock Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: April 20, 2023
+Added: Form of Existing Warrant Amendment.
+Added: Current Report on Form 8-K (File No.
+Added: April 20, 2023
+Added: Form of Series A Common Stock Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: Form of Series B Common Stock Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: Form of Series A/B Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: December 8, 2023
+Added: Form of Placement Agent Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: December 8, 2023
+Added: Form of Series C/D Warrant.
+Added: Current Report on Form 8-K (File No.
July 12, 2024
−Removed: Form of Inducement Letter Agreement, dated July 12, 2024, by and between Phio Pharmaceuticals Corp.
−Removed: and the Holders.
+Added: Form of Placement Agent Warrant.
Current Report on Form 8-K (File No.
July 12, 2024
−Removed: Offer Letter, executed July 16, 2024, by and between the Company and Robert M.
+Added: Form of Series E Common Stock Warrant.
Current Report on Form 8-K (File No.
−Removed: August 1, 2024
−Removed: Sarbanes-Oxley Act Section 302 Certification of Principal Executive
−Removed: Sarbanes-Oxley Act Section 302 Certification of Principal Financial Officer.
+Added: December 20, 2024
+Added: Form of Placement Agent Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: December 20, 2024
+Added: Form of Series F Common Stock Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: December 26, 2024
+Added: Form of Placement Agent Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: December 26, 2024
+Added: Form of Series G Common Stock Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: January 14, 2025
+Added: Form of Placement Agent Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: January 14, 2025
+Added: Form of Series H Common Stock Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: January 15, 2025
+Added: Form of Placement Agent Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: January 15, 2025
+Added: Form of Series I Common Stock Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: January 17, 2025
+Added: Form of Placement Agent Warrant.
+Added: Current Report on Form 8-K (File No.
+Added: January 17, 2025
+Added: Form of Securities Purchase Agreement, dated January 13, 2025,
+Added: Current Report on Form 8-K (File No.
+Added: January 14, 2025
+Added: by and between the Company and each of the Purchasers signatory thereto.
+Added: Form of Securities Purchase Agreement, dated January 14, 2025,
+Added: Current Report on Form 8-K (File No.
+Added: January 15, 2025
+Added: by and between the Company and each of the Purchasers signatory thereto.
+Added: Form of Securities Purchase Agreement, dated January 16, 2025,
+Added: Current Report on Form 8-K (File No.
+Added: January 17, 2025
+Added: by and between the Company and each of the Purchasers signatory thereto.
+Added: First Amendment to the Employment Agreement of Robert J.
+Added: Bitterman, dated March 25, 2025, by and between the Company and Robert Bitterman.
+Added: Annual Report on Form 10-K (File No.
+Added: March 31, 2025
Sarbanes-Oxley Act Section 302 Certification of Principal Executive Officer.*
Sarbanes-Oxley Act Section 302 Certification of Principal Financial Officer.*
+Added: Sarbanes-Oxley Act Section 906 Certification of Principal Executive Officer and Principal Financial Officer.**
Inline XBRL Instance Document.*
8 unchanged sentences
Furnished herewith and not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section or incorporated by reference into any filing under the Securities Act or the Exchange Act.
−Removed: Pursuant to the requirements
−Removed: of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto
−Removed: duly authorized.
+Added: Indicates a management contract or compensatory plan or arrangement.
+Added: Pursuant to the requirements of the Securities
+Added: Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized
+Added: on May 15, 2025.
Phio Pharmaceuticals Corp.
2 unchanged sentences
(as Principal Executive Officer)
−Removed: November 14, 2024
/s/ Robert M.
−Removed: Vice President, Chief Financial Officer
+Added: Chief Financial Officer
(as Principal Financial Officer)
−Removed: November 14, 2024
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.